ReviewClinical lymphoma, myeloma & leukemia2012
Adherence to BCR-ABL inhibitors: issues for CML therapy.
Review in Clinical lymphoma, myeloma & leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An Adaptable Framework for Factors Contributing to Medication Adherence: Results from a Systematic Review of 102 Conceptual Frameworks.Journal of general internal medicine · 2021Pooled it
- Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.Blood · 2025Trial
- Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.Clinical pharmacokinetics · 2024Trial
- Feasibility and Implementation of an eHealth Dashboard for the Remote Monitoring of Dutch Patients With Chronic Myeloid Leukemia: Multimethods Approach.JMIR cancer · 2026Article
- Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission.JCO clinical cancer informatics · 2025Article
- Impact of Patient Personality on Adherence to Oral Anticancer Medications: An Opportunity?JMIR cancer · 2024Article
- A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.Pharmaceutics · 2024Article
- Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.The Korean journal of internal medicine · 2021Article
- Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.International journal of environmental research and public health · 2021Article
- Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.Cancer management and research · 2020Article
- Early Management of CML.Current hematologic malignancy reports · 2019Review
- Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.Journal of managed care & specialty pharmacy · 2019Article
- Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population.Mediterranean journal of hematology and infectious diseases · 2019Article
- First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.American journal of hematology · 2017Article
- Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.Current hematologic malignancy reports · 2016Review
- Milestones and monitoring.Current hematologic malignancy reports · 2015Review
- A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.Blood · 2014Article
- European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.Cancer science · 2014Article
- Protecting pediatric oncology patients from influenza.The oncologist · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Treatment for chronic myeloid leukemia (CML) has improved substantially in the past 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely receive therapy for the remainder of their lives. In this situation, adherence to medication becomes a concern. Adherence to therapy for chronic health conditions, including CML, has been demonstrated to be poor. Studies have shown nonadherence in CML to be common in one-third or more of patients, and 100% adherence is rare. Furthermore, evidence suggests that reduced adherence to BCR-ABL inhibitors is associated with reduced efficacy and increased healthcare costs. Factors that can cause nonadherence, including dose, toxicity, time from diagnosis to prescription, and the number of concomitant medications, should be addressed and monitored by the physician. To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.